Publication:
Delftibactin-A, a Non-ribosomal Peptide With Broad Antimicrobial Activity.

dc.contributor.authorTejman-Yarden, Noa
dc.contributor.authorRobinson, Ari
dc.contributor.authorDavidov, Yaakov
dc.contributor.authorShulman, Alexander
dc.contributor.authorVarvak, Alexander
dc.contributor.authorReyes, Fernando
dc.contributor.authorRahav, Galia
dc.contributor.authorNissan, Israel
dc.date.accessioned2023-02-08T14:37:01Z
dc.date.available2023-02-08T14:37:01Z
dc.date.issued2019-10-15
dc.description.abstractThe rapid emergence of drug resistant bacteria is occurring worldwide, outpacing the development of new antibiotics. It is known that some of the main sources of antibiotics are the bacteria themselves, many of which are secondary metabolites of Gram positive bacteria. Siderophores, which are secondary metabolites, function as natural chelators (e.g., iron). They are produced and secreted by many bacteria and have been experimented on as "carriers" of several types of antibiotics that pass the cell membrane of challenging Gram negative bacteria. Delftibactin A is a non-ribosomal peptide (NRP), which is known to detoxify gold in Delftia spp. and form gold nuggets, and is considered to be a siderophore. In this study we demonstrate that the supernatant from novel environmental isolates of Delftia spp. have antimicrobial activity. We characterized the active fraction and identified delftibactin A as a compound with antimicrobial activity. Delftibactin A exhibits potent antimicrobial activity against Gram positive multi drug resistant (MDR) bacteria like Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin resistant Enterococcus (VRE), and also against the Gram negative pathogens Acinetobacter baumannii and Klebsiella pneumoniae. We discovered that the production of delftibactin A is greatly influenced by temperature. Furthermore, we have demonstrated the possibility of utilizing delftibactin A as a siderophore carrier of toxic metals such as gallium into Gram negative bacteria. These findings expose new opportunities of yet unexploited natural products such as delftibactin A, which have been known for other bacterial uses, as potent factors in the battle against MDR bacteria.
dc.identifier.doi10.3389/fmicb.2019.02377
dc.identifier.issn1664-302X
dc.identifier.pmcPMC6808179
dc.identifier.pmid31681234
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808179/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fmicb.2019.02377/pdf
dc.identifier.urihttp://hdl.handle.net/10668/14624
dc.journal.titleFrontiers in microbiology
dc.journal.titleabbreviationFront Microbiol
dc.language.isoen
dc.organizationFundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía)
dc.organizationFundación MEDINA
dc.page.number2377
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDelftia
dc.subjectantimicrobial
dc.subjectdelftibactin-A
dc.subjectnew antibiotic
dc.subjectsiderophore
dc.titleDelftibactin-A, a Non-ribosomal Peptide With Broad Antimicrobial Activity.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC6808179.pdf
Size:
3.61 MB
Format:
Adobe Portable Document Format